Three short films created through an Eli Lilly-sponsored initiative are premiering at the Tribeca Festival, furthering the ...

Teva Pharmaceuticals plans to remove 250 jobs at its CDMO unit over the next two years, Israeli business news outlet Globes ...

Germany’s new healthcare reform initiative has already led two global drugmakers to slice their planned investments in the ...

Almost two-thirds of Americans who have asked artificial intelligence tools for medical advice acted on the guidance without ...

Gilead’s lenacapavir has been on the market since 2022, when it was approved in the U.S. as Sunlenca for twice-yearly ...

The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing ...

For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first ...

Twenty-six years of chasing New York City sex crimes as the face of “Law & Order: Special Victims Unit” has prepared ...

It’s a sign of the times that this year’s American Diabetes Association (ADA) Scientific Sessions meeting in New Orleans ...

The new expansion covers all patients 6 and older, regardless of their inhibitor status. The new nod also opens up the ...

After dodging a layer of U.S. scrutiny thus far, Chinese CDMO WuXi AppTec is back in the government’s crosshairs. The company is now listed on the U.S. Department of War’s newly updated roster of ...

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed.